Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment.
Science translational medicine
View this publicationScience translational medicine
View this publicationEuropean journal of immunology
View this publicationProceedings of the National Academy of Sciences of the United States of America
View this publicationClinical drug investigation
View this publicationThe British journal of dermatology
View this publicationThe Journal of experimental medicine
View this publicationJournal of clinical medicine
View this publicationNeuroImage. Clinical
View this publicationScientific reports
View this publicationThe Journal of investigative dermatology
View this publication